- Our Doctors
- Dr Paul Miller
Dr Paul Miller
BSc (Hons) Cell Biology, MB BChir (Cantab), DPhil Clinical Medicine (Oxon), PgCert Neuroimaging for Research, PgDip Medical Education, PgDip Health Research, MRCP (London), Consultant Medical Oncologist
Languages spoken
English
Expert in
Treatment of cancers of the pancreas, bile ducts (cholangiocarcinoma), liver, oesophagus, stomach, and duodenum
Overview
Centres
Specialises in
Treatments
Dr Paul Miller is a Consultant Medical Oncology who specialises in the treatment of cancers of the pancreas, bile ducts (cholangiocarcinoma), liver, oesophagus, stomach, and duodenum. Also, he treats cancers of unknown primary. In 2022, he was appointed Consultant Medical Oncologist at Churchill Hospital, Oxford University Hospitals NHS Foundation Trust. He is a principal investigator on several HPB and OG clinical trials.
Dr Miller originally studied Cell Biology in Durham University obtaining a first-class honours degree. He qualified from University of Cambridge medical school in 2008 before undertaking an Academic Foundation Programme in Manchester including a rotation at The Christie. In Oxford he completed an Academic Clinical Fellowship followed by DPhil in Clinical Medicine at the Ludwig Institute for Cancer Research University of Oxford. He completed Medical Oncology training while holding a NIHR Clinical Lectureship.
Dr Miller’s research interests include clinical trials and basic science research in pancreato-biliary cancers.
.svg){kind=icon}
Career positions
Current position(s)
- Oxford
- Churchill Hospital
- Oxford University Hospitals NHS Foundation Trust
Year qualified
2008
Expertise and interests
Clinical Interests
- Dr Miller’s research interests include clinical trials and basic science research in pancreato-biliary cancers.
Expertise
- Treatment of cancers of the pancreas, bile ducts (cholangiocarcinoma), liver, oesophagus, stomach, and duodenum
Interests
- Hepato-Pancreato-Biliary (HPB) cancer
- Oesophagogastric (OG) cancer
- Cancer of Unknown Primary (CUP)
- Clinical trials for HPB, OG and CUP malignancies
- Applying molecular testing to optimise cancer management decision-making
Professional memberships
- Member of the Royal College of Physicians (MRCP)
- Member of the European Society for Medical Oncology (ESMO)
- Member of the Association of Cancer Physicians (ACP)
- Member of the British Medical Association (BMA)
Publications & affiliations
- Miller, P. et al. p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer
- Miller, P. et al Quantitative evaluation of white matter tract DTI parameter changes in gliomas using nonlinear registration
Awards
- Gordon Holmes Prize for Clinical Neuroscience (Royal Society of Medicine)
- CRUK Oxford Centre Clinical Research Training Fellowship Prize